Medtronic's Minimally Invasive Therapies Group has launched a 2,500-patient international study to evaluate the impact of its superDimension navigation system, a device with the aim of obtaining lung tissue biopsies from the periphery of the lungs.
The system features LungGPS technology to enable Electromagnetic Navigation Bronchoscopy procedures. ENB procedures help healthcare access areas of the lung that are difficult to reach, allowing for earlier diagnosis of lung diseases and more personalized treatment.
The study will take place in 75 centers around the globe. Patients will be followed for 24 months, the medical device giant says.
According to the American Cancer Society, lung cancer remains the number one cancer killer in the world. — Michael Cipriano